LEO Pharma is a global pharmaceutical company founded in 1908, specializing in medical dermatology. With a strong focus on research and development, LEO Pharma is committed to delivering innovative treatments and solutions for a wide range of skin diseases. The company's mission is to help people achieve healthy skin by advancing the science of dermatology, improving patient care, and providing access to effective therapies worldwide. LEO Pharma's portfolio covers conditions such as psoriasis, eczema (atopic dermatitis), skin infections, and rare skin diseases. Headquartered in Denmark, the company has a significant global presence, with R&D, manufacturing, and commercial operations across numerous countries.
The Ballerup headquarters serves as the central hub for LEO Pharma's global operations, including corporate management, strategic planning, research and development leadership, and global marketing.
A modern and expansive campus featuring state-of-the-art research laboratories, collaborative office spaces, and employee amenities. The site is designed to foster innovation and cross-functional teamwork.
LEO Pharma's headquarters fosters a science-driven, patient-centric, and collaborative work environment. It reflects Danish work culture principles, emphasizing work-life balance, employee well-being, integrity, and a passion for innovation in dermatology.
The headquarters is pivotal for LEO Pharma's global strategy execution, housing key decision-makers and central R&D functions that drive the company's pipeline and product portfolio in medical dermatology.
LEO Pharma has an extensive global footprint, with its products available in more than 130 countries. The company supports a wide range of functions worldwide, including research and development in multiple centers, manufacturing facilities (e.g., in Denmark, France, Ireland), commercial operations and sales & marketing teams in major regions like Europe, North America, Asia-Pacific, and Latin America, as well as global clinical trial management and medical affairs.
Industriparken 55
Ballerup
Capital Region of Denmark
Denmark
Address: LEO Pharma Inc., 7 Giralda Farms, Madison, NJ 07940, USA
Crucial for serving one of the world's largest pharmaceutical markets, focusing on bringing LEO Pharma's dermatological treatments to patients and healthcare professionals in the United States.
Address: LEO Pharma UK/IE, Horizon, Honey Lane, Hurley, Berkshire, SL6 6RJ, UK
Key hub for one of Europe's significant healthcare markets, ensuring access to LEO Pharma's dermatology solutions for patients in the UK and Ireland.
Address: LEO Pharma France, 2 Rue René Caudron, CS 40070, 78960 Voisins-le-Bretonneux, France
Supports LEO Pharma's presence in continental Europe, delivering dermatological treatments and engaging with the French healthcare system and patient communities.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, LEO Pharma' leadership includes:
LEO Pharma has been backed by several prominent investors over the years, including:
LEO Pharma has strategically strengthened its executive leadership over the past 12 months, particularly with key appointments in R&D and Finance. These changes are aimed at driving the company's 2030 strategy focused on innovation and growth in medical dermatology.
Discover the tools LEO Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
LEO Pharma's standard email format typically combines an employee's first and last name, or initials and last name, with the @leo-pharma.com domain. One of the commonly observed patterns is [firstname].[lastname]@leo-pharma.com.
[firstname].[lastname]@leo-pharma.com
Format
john.doe@leo-pharma.com
Example
90%
Success rate
LEO Pharma Press Release • May 21, 2024
LEO Pharma A/S and Krystal Biotech, Inc. announced a definitive agreement where LEO Pharma will acquire exclusive rights to commercialize B-VEC (beremagene geperpavec) for Epidermolysis Bullosa (EB) in all markets outside the U.S., while Krystal retains U.S. rights. LEO Pharma will make an upfront payment of $100 million....more
LEO Pharma Press Release • February 29, 2024
LEO Pharma announced the appointment of Kreena Dhiman as its new Executive Vice President for Global Research & Development, effective March 1, 2024. She will lead the company's R&D strategy and efforts to advance its pipeline of innovative dermatology treatments....more
LEO Pharma Press Release • February 21, 2024
LEO Pharma reported solid performance in 2023 with revenue increasing by 9% (5% in constant exchange rates) to DKK 11.4 billion, primarily driven by its dermatology portfolio. The company also highlighted significant progress in its R&D pipeline....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including LEO Pharma, are just a search away.